Apellis Pharmaceuticals Inc (NASDAQ:APLS) gets upgraded to Buy by B. Riley with a price target of $27.00

Analyst Ratings For Apellis Pharmaceuticals Inc (NASDAQ:APLS)

Story continues below

Today, Apellis Pharmaceuticals Inc (NASDAQ:APLS) stock received an upgrade by B. Riley from Neutral to Buy with a price target of $27.00.

There are 6 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Apellis Pharmaceuticals Inc (NASDAQ:APLS) is Buy with a consensus target price of $35.40 per share, a potential 96.99% upside.

Some recent analyst ratings include

  • 7/30/2018-B. Riley Upgrade from a “Neutral ” rating to a ” Buy” rating.
  • 7/10/2018-Cowen initiated coverage with a Outperform rating.
  • 6/27/2018-Cantor Fitzgerald Reiterated Rating of Buy.
  • 12/4/2017-Evercore ISI initiated coverage with a Outperform rating.
  • 12/4/2017-Citigroup initiated coverage with a Buy rating.

Recent Insider Trading Activity For Apellis Pharmaceuticals Inc (NASDAQ:APLS)
Apellis Pharmaceuticals Inc (NASDAQ:APLS) has insider ownership of 9.30% and institutional ownership of 36.72%.

  • On 5/24/2018 Lukas Scheibler, Insider, bought 2,935 with an average share price of $20.37 per share and the total transaction amounting to $59,785.95.
  • On 11/13/2017 Global Strategic Fund I Venbio, Major Shareholder, bought 127,515 with an average share price of $14.00 per share and the total transaction amounting to $1,785,210.00.

About Apellis Pharmaceuticals Inc (NASDAQ:APLS)
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology. The company develops APL-2 for intravitreal injection that is an injection into the eye, as well as subcutaneous injection, which is an injection into the tissue under the skin. It also develops APL-9 for intravenous administration in systemic indications, which is in single ascending dose Phase I clinical trial. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.

Recent Trading Activity for Apellis Pharmaceuticals Inc (NASDAQ:APLS)
Shares of Apellis Pharmaceuticals Inc closed the previous trading session at 17.64 up +1.07 6.46% with 17.25 shares trading hands.

An ad to help with our costs